2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Abstract Number: 016

Still’s Disease Associated Lung Disease: Experience from a Tertiary Italian Centre
Abstract Number: 017

High-Frequency Ultrasound Evaluation Predicts Disease Activity in Juvenile Localized Scleroderma
Abstract Number: 018

Abnormal Cortical Grey Matter, White Matter and Subcortical Grey Matter Morphometry is Associated with Disease Features and Quality of Life in Patients with Craniofacial Localized Scleroderma
Abstract Number: 019

Effects of Childhood-Onset Interferon-Driven Autoimmune Disorders on Brain Volume and Executive Function: A Pilot Analysis in JDM and Childhood-Onset SLE
Abstract Number: 020

Building Consensus on Key Research Domains and Research Topics in Childhood-onset Neuropsychiatric Lupus: An International Prioritization Initiative
Abstract Number: 021

Medication Changes and Lung Disease Activity in Systemic JIA: Six-Month Follow-Up of CARRA Registry SJIA-LD Cohort
Abstract Number: 022

Mental Health concerns in Patients with Juvenile Idiopathic Arthritis and Their Caregivers: A Systematic Review
Abstract Number: 023

Screening Tools for Spondyloarthropathies among Patients with Inflammatory Bowel Disease: A Scoping Review
Abstract Number: 024

Therapeutic Plasma Exchange in Pediatric Autoimmune Encephalitis
Abstract Number: 025

Longitudinal Single Cell Transcriptomic Analysis of Type I and II Interferon (IFN) Response Genes (IRG) in Refractory Juvenile Dermatomyositis (JDM) Patients with Baricitinib Treatment
Abstract Number: 026

Treatment strategies for articular flares in JIA patients receiving biologic therapy
Abstract Number: 027

An Examination of Brain-age-related Deviations from Normative Neurodevelopmental Trajectory in Children with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 028

Are You Positive About this Positive ANA Referral? Outcomes for ANA Based Referrals to Pediatric Rheumatology and Subsequent Disease Development
Abstract Number: 029

Oral vs Subcutaneous Methotrexate at High Dose for Pediatric Anterior Uveitis
Abstract Number: 030

Musculoskeletal and Nail Ultrasound Findings in Children with Psoriasis: A Case-Control Study

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].